USD
$0.00
(0.00%
)At Close (As of Sep 9, 2025)
$3.40B
Market Cap
-
P/E Ratio
-1.83
EPS
$39.51
52 Week High
$16.10
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $664M |
Total Revenue | $781M |
Cost Of Revenue | $118M |
Costof Goods And Services Sold | $118M |
Operating Income | -$165M |
Selling General And Administrative | $501M |
Research And Development | $328M |
Operating Expenses | $829M |
Investment Income Net | - |
Net Interest Income | -$28M |
Interest Income | $13M |
Interest Expense | $40M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.8M |
Income Before Tax | -$197M |
Income Tax Expense | $1.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$198M |
Comprehensive Income Net Of Tax | - |
Ebit | -$156M |
Ebitda | -$155M |
Net Income | -$198M |
Field | Value (USD) |
---|---|
Total Assets | $885M |
Total Current Assets | $789M |
Cash And Cash Equivalents At Carrying Value | $411M |
Cash And Short Term Investments | $411M |
Inventory | $81M |
Current Net Receivables | $272M |
Total Non Current Assets | $96M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $25M |
Other Non Current Assets | - |
Total Liabilities | $657M |
Total Current Liabilities | $186M |
Current Accounts Payable | $39M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $6.8M |
Total Non Current Liabilities | $471M |
Capital Lease Obligations | $17M |
Long Term Debt | $453M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $470M |
Other Current Liabilities | $140M |
Other Non Current Liabilities | $8M |
Total Shareholder Equity | $229M |
Treasury Stock | - |
Retained Earnings | -$3B |
Common Stock | $12K |
Common Stock Shares Outstanding | $124M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$88M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.8M |
Capital Expenditures | $403K |
Change In Receivables | - |
Change In Inventory | -$11M |
Profit Loss | - |
Cashflow From Investment | -$403K |
Cashflow From Financing | $149M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $4.5M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$198M |
Field | Value (USD) |
---|---|
Gross Profit | $664M |
Total Revenue | $781M |
Cost Of Revenue | $118M |
Costof Goods And Services Sold | $118M |
Operating Income | -$165M |
Selling General And Administrative | $501M |
Research And Development | $328M |
Operating Expenses | $829M |
Investment Income Net | - |
Net Interest Income | -$28M |
Interest Income | $13M |
Interest Expense | $40M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.8M |
Income Before Tax | -$197M |
Income Tax Expense | $1.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$198M |
Comprehensive Income Net Of Tax | - |
Ebit | -$156M |
Ebitda | -$155M |
Net Income | -$198M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.